Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Study crawled date : 2022 - 10 - 20 save search
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
Published: 2022-10-20 (Crawled : 23:00) - biospace.com/
CSTL | $19.28 0.42% 0.41% 130K
|
Health Technology
|
| O: -0.23%
H: 4.71%
C: -0.41%
decisiondx test results perform study
Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat
Published: 2022-10-20 (Crawled : 21:00) - contravir.com
HEPA | News | $2.11 -0.09% -0.09% 73K
|
Health Technology
|
| O: 1.52%
H: 0.0%
C: -1.36%
pharmaceuticals food publication study
Consumer Purchase Intent More than Doubles When Socially Conscious Brands Engage Advertising Media Partners that Share Common Values, According to UM's Future Impact Study
Published: 2022-10-20 (Crawled : 16:00) - prnewswire.com
LEVI | $20.55 0.19% 0.0% 1.7M
|
Consumer Non-Durables
|
| O: -0.07%
H: 2.53%
C: -0.99%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.47%
H: 0.45%
C: 0.07%
media impact brands study
Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia
Published: 2022-10-20 (Crawled : 12:20) - globenewswire.com
EYEN | $0.574 8.12% 7.51% 1.4M
|
Health Technology
|
| O: 4.37%
H: 4.78%
C: -9.16%
treatment potential positive presbyopia study
Silo Pharma Announces Data Supporting Therapeutic Potential of SPC-14 for Alzheimer’s Disease in Pre-Clinical Study
Published: 2022-10-20 (Crawled : 12:20) - globenewswire.com
SILO | $1.97 0.0% 40K
|
Finance and Insurance
|
| O: 2.72%
H: 1.22%
C: -15.27%
spc-14 pharma disease pre-clinical alzheimer’s potential study
Garmin Health hits key milestone with completion of 500th research study
Published: 2022-10-20 (Crawled : 12:00) - biospace.com/
GRMN | $139.52 -0.85% 0.0% 2.9M
|
Electronic Technology
|
| O: 0.09%
H: 0.98%
C: -0.5%
research health milestone study
First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial
Published: 2022-10-20 (Crawled : 12:00) - prnewswire.com
PTN | $1.84 -2.65% 0.05% 150K
|
Health Technology
|
| O: 1.68%
H: 0.62%
C: -4.55%
pl8177 trial study phase 2 ulcerative colitis
First vitiligo patient enrolled in afamelanotide monotherapy study
Published: 2022-10-19 (Crawled : 01:00) - clinuvel.com
CLVLY | $9.75 31.84% 1.6K
|
Professional, Scientific, and T...
|
| O: -2.48%
H: 0.99%
C: 0.99%
study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.